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aTo the Editor: Hypertension (HTN) is associated with adverse
prognosis, accompanied by changes in left ventricular (LV) size,
structure, and function (1,2). Echocardiographic LV measures,
including left ventricular mass index (LVMI), are correlated with
outcome among patients with systemic HTN (3). Despite known
adverse effects of HTN (4) and several drugs for its treatment,
many patients have persistent HTN despite aggressive medical
therapy.
The Rheos system uses baroreflex activation therapy (BAT) to
chronically activate the baroreflex at the carotid sinus with electri-
cal impulses from a pulse generator. Preliminary results showed
that BAT significantly reduced blood pressure in patients with
drug-resistant HTN (5). This investigation aimed to assess the
impact of BAT on echocardiographic measures of cardiac structure
and function in patients with drug-resistant HTN.
As a substudy of the proof-of-principle DEBuT-HT (Device
Based Therapy in Hypertension Extension Trial; NCT00710294)
and U.S. feasibility trials (NCT01077180 and NCT00710190),
his investigation involved acquiring serial echocardiograms on 34
atients at 8 different centers, of whom 21 patients had complete
aired data after 1 year of BAT. Inclusion criteria included
rug-resistant HTN with systolic blood pressure (SBP) 160 mm
g and stable medication of 3 anti-HTN drugs including a
iuretic at maximally tolerated dose. Ethics committees and/or
nstitutional review boards reviewed and approved the study
rotocol. All participants provided written informed consent.
Office heart rate (HR) and BP were obtained using auto-
ated electronic BP measurement devices (BPM-200, BpTRU
edical Devices, Coquitlam, British Columbia, Canada; or
mron 907XL, Omron Healthcare, Kyoto, Japan) using stan-
ard methods.
Patients were implanted with the Rheos system (CVRx Inc.,
inneapolis, Minnesota), consisting of a pulse generator and leads
unneled subcutaneously to attach to each carotid sinus. Therapy
as activated approximately 1 month after device implantation.
timulation parameters were gradually adjusted over time such
hat optimal therapy was delivered by 4 months after device
mplantation.
Transthoracic echocardiographic and Doppler imaging were
erformed by trained sonographers before Rheos implant and 3
nd 12 months after active BAT. Left ventricular measurements
ere made from 2-dimensional images using standard techniques
6). Images were analyzed with commercially available software
ProSolv version 3.0.48, Prosolv Cardiovascular Solutions, India- rapolis, Indiana) by a single investigator blinded to treatment
tatus, study visit time point, and clinical data.
Comparisons before and after intervention were made with
aired t tests with the exception of 3 variables that were found to
ave non-normal distributions. The Wilcoxon signed-rank non-
arametric test was used to test for significant change over time in
hose variables found to have non-normal distributions. Statistical
nalyses were performed with SAS (version 9.1.3, SAS Institute
nc., Cary, North Carolina). Data are presented as means SE for
ariables in which parametric testing was performed and as median
nd quartiles for variables in which nonparametric testing was
erformed.
The study included 34 patients (19 men, 15 women; age 52.5
.8 years). Follow-up echocardiographic data after 12 months of
AT was available for 21 patients. No significant differences in
esponse to BAT for variables characterizing cardiac structure and
unction or hemodynamic response (SBP, diastolic BP, and HR)
ere observed between those with versus without 12-month
ollow-up data at the 3-month time point. At the time of
nrollment, patients averaged 5.3  0.3 anti-HTN medications
range 3 to 10).
Systolic and diastolic BP, HR, and rate pressure product were
ignificantly reduced following 3 and 12 months of BAT (Table 1).
ne year of BAT reduced left atrial (LA) dimension, LV wall
hicknesses, LV mass, and LV stroke work (p 0.001). Significant
eduction in mitral A-wave velocity, LA dimension, and LVMI
uggested reduced LV diastolic filling pressures with BAT. Ab-
ormal LVMI was present at pre-implant in 17 of 21 patients with
ata at 1 year. Eight of those 17 patients (47%) had LVMI in the
eference range after 12 months. No signs of deteriorating LV
ystolic function were present (i.e., no reduced LV ejection
raction, no increased LV end-diastolic diameter).
Our findings indicated that BAT improved LA and LV
tructure and function in patients with drug-resistant HTN against
background of aggressive medical therapy. Previous trials of
ntihypertensive medications have found LVMI reductions of 2%
o 14% with monotherapy (4,7,8). Baroreflex activation therapy
educed LVMI by approximately 18%, with baseline LVMI being
reater than that in many previous studies. This large reduction in
VMI achieved by BAT was incremental to benefits conferred by
ntihypertensive medications (including 91% of patients using
ngiotensin-converting enzyme inhibitors and/or angiotensin II
eceptor blockers).
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April 26, 2011:1787–91This study had limitations, including lack of control group,
potential placebo effect, and medication adjustment per physician
discretion (medication actually decreased at 12 months [data not
shown], suggesting that remodeling was not explained by intensi-
fied medication).
In summary, significant improvements were observed in LA and
LV structure and function after chronic BAT in patients with
resistant HTN. Cardioprotective effects of BAT on BP and LV
structure and function are being further evaluated in ongoing
randomized clinical trials.
*John D. Bisognano, MD, PhD
*Department of Internal Medicine, Cardiology Division
University of Rochester Medical Center
601 Elmwood Avenue
Box 679-7
Rochester, New York 14642-8679
E-mail: john_bisognano@urmc.rochester.edu
Christopher L. Kaufman, PhD
David S. Bach, MD
Eric G. Lovett, PhD
Peter de Leeuw, MD
for the DEBuT-HT and Rheos Feasibility Trial Investigators
doi:10.1016/j.jacc.2010.11.048
lease note: This study was funded by CVRx Inc., Minneapolis, Minnesota. Drs.
isognano, Bach, and de Leeuw have received modest research grant support from
VRx and have previously or are currently serving as consultants/advisors for CVRx.
Baseline and Change in Echocardiographic Variables inTable 1 Baseline and Change in Echocardiographi
Variable
Cardiac structure
LAD, mm
LADi, mm/m2
Septal wall thickness, mm
LV posterior wall thickness, mm
Relative wall thickness
LVOT diameter, mm
LVEDD, mm
LVESD, mm
LV mass, g
LV mass index, g/m2
Cardiac function
LVEF, %
Stroke work
Mitral E-wave velocity, cm/s
Mitral A-wave velocity, cm/s
Mitral E/A
MWFS, %
SBP, mm Hg
DBP, mm Hg
Pulse pressure, mm Hg
Heart rate, beats/min
Rate pressure product, beats/min  mm Hg 1
Data are presented as mean  SE, with the exception of LVEF, sep
distributions and thus are expressed as median (interquartile range). *
baseline).
DBP  diastolic blood pressure; LAD  left atrial dimension; LADi
end-diastolic diameter; LVEF left ventricular ejection fraction; LVESD
mitral E/A  mitral E- to A-wave ratio; MWFS  midwall fractional shrs. Kaufman and Lovett are employees of CVRx.EFERENCES
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nt Cohortables in Patient Cohort
eline
34)
 3 Months
(n  34)
 12 Months
(n  21)
 1.3 1.2 0.5* 2.4 0.8†
 0.5 0.6 0.2* 1.2 0.3†
to 16) 1 (2 to 0)‡ 1 (2 to 0)‡
to 15) 1 (1 to 0)‡ 1 (2 to 1)‡
 0.02 0.02 0.01* 0.05 0.01‡
 0.3 0.5 0.2† 1.0 0.3†
 0.9 0.9 0.5 1.6 0.5†
 0.8 1.3 0.6* 2.4 1.0*
 15.7 39.8 6.5‡ 52.8 9.3‡
 6.0 18.0 2.7‡ 24.6 3.9‡
to 68) 1 (0 to 3)† 2 (0 to 4)*
 8.8 29.5 8.8† 31.3 10.5†
 0.04 0.01 0.02 0.06 0.03
 0.03 0.03 0.02 0.11 0.03†
 0.10 0.01 0.05 0.07 0.09
 0.5 1.0 0.4† 1.7 0.6†
 4.3 23.6 5.4‡ 25.7 5.7‡
 3.0 11.7 3.4† 12.9 4.3†
 2.7 11.9 3.1‡ 12.8 2.9‡
 1.8 4.5 1.5† 2.7 1.8
 565 2,197 521‡ 1,994 606‡
l thickness, and LV posterior wall thickness, which had non-normal
5 (versus baseline). †p 0.01 (versus baseline). ‡p 0.001 (versus
trial dimension index; LV  left ventricular; LVEDD  left ventricular
entricular end-systolic diameter; LVOT left ventricular outflow tract;
g; SBP  systolic blood pressure.Patiec Vari
Bas
(n 
44.8
20.9
14 (13
14 (13
0.56
19.6
50.0
31.0
302.0
138.9
65 (62
199.6
0.78
0.84
1.02
13.9
179.6
104.4
74.9
72.4
3,267
tal wal
p 0.0
 left aJ Hypertens 1995;13:1325–34.
